Cantex's pipeline has two product candidates in clinical development for diseases where innovative and more effective treatments are greatly needed. DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML). Dicopp® for the treatment of metastatic pancreatic cancer, recurrent/refractory multiple myeloma, and recurrent pediatric sarcoma.
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16915,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive


Cantex has two product candidates in clinical development:

DSTAT (formerly known as CX-01):


  • Licensed to Chimerix, Inc. in July 2019. Continued participation in development via Joint Development Committee.
  • A new chemical entity, derived from heparin, with very low anticoagulant activity
  • Neutralizes activity of heparin-binding proteins that play a role in the resistance of leukemia cells to chemotherapy
  • Randomized Phase 2 study in acute myeloid leukemia (AML) suggested DSTAT + 7+3 improves event-free and relapse-free survival as well as overall survival without additive toxicity
  • Most patients who achieved complete response remain relapse free 15+ months after initial treatment
  • Phase 3 clinical trial in AML expected to begin in late 2020.
  • DSTAT has received Orphan Drug and Fast Track Designations from the FDA for the treatment of AML
  • Pre-clinical data suggests that DSTAT may reduce inflammation, decrease immune cell infiltration and prevent and treat coagulation disorders associated with acute lung injury
  • Phase 2/3 study of DSTAT in COVID-19 associated acute lung injury is in progress



  • Proprietary combination of disulfiram + copper which has been extensively reported to have cancer cell killing mechanisms, including proteasome inhibition and inhibition of activity of DNA repair enzymes
  • Highly cytotoxic to cancer stem cells in a broad range of malignant diseases
  • Phase 2 clinical study in metastatic pancreatic cancer in progress
  • Phase 1/2 studies in recurrent/refractory multiple myeloma and in recurrent pediatric sarcoma expected to begin in the second half of 2020.
  • Cantex owns issued and pending intellectual property for Dicopp®
  • Dicopp® is a 505(b)(2)product